Tubulis
About
Tubulis generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties, demonstrating durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Their lead programs, TUB-040 and TUB-030, are being evaluated in the clinic for high-need solid tumor indications. Tubulis aims to expand the therapeutic potential of ADCs for patients, partners, and through their pipeline.
Key facts
At-a-glance profile data
- Website
- gilead.com
- Headquarters
- Munich, Germany
- Founded
- 2013
- Employees
- 118
- Total funding
- $434M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 16 Oct 2025 | Series C | $333M | EQT Life Sciences, Nextech Invest |
| 10 May 2023 | Undisclosed round | $60M | Andera Partners, BioMedPartners, Evotec, Fund+ |
| 27 Apr 2021 | Undisclosed round | $30M | BioMedPartners, Coparion, Seventure Partners, Vesalius Biocapital III, Wellington Partners |
| 1 Aug 2019 | Undisclosed round | $11M | High-Tech Gründerfonds, Seventure Partners, Coparion |
Tech stack
Detected on gilead.com and in its job posts, last scanned 7 Sept 2026. Run your own scan
- Frontend
- Tailwind CSS, Bootstrap, TypeScript
- Backend
- Python, Java
- Analytics
- Google Tag Manager
- Observability
- Datadog
- CDN
- Cloudflare
- Hosting
- Google Cloud, AWS, Azure
- Email provider
- Proofpoint
- Hiring platform
- Workday
- DevOps
- Terraform, Docker, Kubernetes
Add first review
Frequently asked
How much funding has Tubulis raised?
Tubulis has raised a total of $434M in funding. The most recent round on record is Series C.
How many employees does Tubulis have?
Tubulis has approximately 118 people on record.